| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,686 | 0,753 | 19:02 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Nanoform Q3 2026 slides: expenses down 35%, GMP readiness nears | 1 | Investing.com | ||
| Do | Earnings Call zu Nanoform im 3. Quartal 2026: Sinkende Betriebskosten und Pipeline-Fortschritte im Fokus | 3 | Investing.com Deutsch | ||
| Do | Nanoform Finland Oyj Q3 Loss Declines | 1 | RTTNews | ||
| Do | Nanoform Finland Oyj: Nanoform Q3 2026 - Agreement signed with global CDMO around Nanoform's Ultra-High-Concentration Biologics technology, targeted readiness for GMP supply during 2H27 | 194 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | November 19, 2026 at 08:10:00 EET
Agreement signed with global CDMO around Nanoform's Ultra-High-Concentration Biologics technology, targeted readiness for GMP... ► Artikel lesen | |
| 20.08. | Earnings Call: Nanoform reduziert Cash-Burn in Q2 2026 und erzielt regulatorische Fortschritte | 1 | Investing.com Deutsch | ||
| 20.08. | Nanoform Q2 2026 slides: cash burn drops 57% as GMP projects rise | 1 | Investing.com | ||
| 20.08. | Nanoform Finland Oyj Q2 Loss Declines | 3 | RTTNews | ||
| NANOFORM FINLAND Aktie jetzt für 0€ handeln | |||||
| 20.08. | Nanoform steigert Umsatz um 16 % und verringert Quartalsverlust | 2 | Investing.com Deutsch | ||
| 20.08. | Nanoform Finland Oyj: Nanoform Q2 2026 - Positive feedback from scientific advice meeting in the UK, significantly improved cash flow and discussions with CDMOs on sterile GMP for our Biologics technology initiated | 766 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | August 20, 2026 at 08:10:00 EEST
Nanoenzalutamide project continues with the communicated multitrack strategy supported by all partners. After a positive scientific... ► Artikel lesen | |
| 05.08. | Nanoform Finland Oyj: Inside information: Positive Feedback from UK MHRA Scientific Advice Meeting regarding Nanoenzalutamide | 559 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | August 05, 2026 at 12:00:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, announced today that it... ► Artikel lesen | |
| 19.05. | Nanoform Finland Oyj: Nanoform Q1 2026 report - Record first quarter revenue, income and gross margin, first exclusivity deal signed around our Biologics technology | 1.072 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | May 19, 2026 at 08:10:00 EEST
Record first quarter revenue, income and gross margin. Revenue grew by 45%, gross margin reached 94% and operating costs fell by... ► Artikel lesen | |
| 12.05. | Nanoform Finland Oyj: Inside information: Nanoform Signs First Exclusivity Agreement for Ultra-High Concentration Subcutaneous Delivery | 953 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | May 12, 2026 at 08:00:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it has... ► Artikel lesen | |
| 21.04. | Nanoform Finland Oyj: Resolutions of Nanoform Finland Plc's Annual General Meeting on April 21, 2026 | 754 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | April 21, 2026 at 12:20:00 EEST
Nanoform Finland Plc (the "Company" or "Nanoform") held its Annual General Meeting for 2026 on April 21, 2026 at the Company's... ► Artikel lesen | |
| 02.03. | Nanoform Finland Oyj: The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees | 1.107 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | March 02, 2026 at 08:10:00 EET
Helsinki, Finland - The Annual General Meeting of Nanoform Finland Plc ("Nanoform") has on 15 April 2025 authorized the company's... ► Artikel lesen | |
| 26.02. | Nanoform Finland Oyj: Nanoform Q4 & FY2025 report - Next: the submission of a marketing authorization application for Nanoenzalutamide in Europe | 1.034 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | February 26, 2026 at 08:10:00 EET
Product kernel strategy continues to gain traction. Nanoenzalutamide: pivotal human fed and fasted study concluded, three more... ► Artikel lesen | |
| 07.01. | Nanoform Finland Oyj: Inside information: Nanoform starts change negotiations as part of announced new midterm business targets for 2030 | 1.063 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | January 07, 2026 at 08:05:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform") starts change negotiations in accordance with the Act on Cooperation.... ► Artikel lesen | |
| 16.12.25 | Nanoform Finland Oyj: Inside information: Nanoform announces new midterm business targets for 2030 | 1.884 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | December 16, 2025 at 07:00:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced new midterm... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 14,000 | +0,57 % | EQS-News: Formycon AG: Zwei Blockbuster, zwei Niche-Buster, ein Smart Portfolio: Formycon nennt Tezspire und Hemlibra als Referenzarzneimittel | EQS-News: Formycon AG
/ Schlagwort(e): Sonstiges
Zwei Blockbuster, zwei Niche-Buster, ein Smart Portfolio: Formycon nennt Tezspire und Hemlibra als Referenzarzneimittel
17.11.2026... ► Artikel lesen | |
| NVE | 63,00 | 0,00 % | Dividendenbekanntmachungen (02.11.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABM INDUSTRIES INC US0009571003 0,29 USD EUR ACUITY INC US00508Y1029 0,2 USD EUR AMERISERV FINANCIAL INC US03074A1025 0,03... ► Artikel lesen | |
| RIBER | 5,630 | 0,00 % | Riber wins Asian order for MBE 6000 production system | ||
| ONTO INNOVATION | 154,15 | -0,61 % | Lehre aus den Nvidia-Zahlen: 3 KI-Kracher ohne Führungskrise - jetzt zugreifen? | © Foto: KI-generiert mit DALL-EBei Nvidia donnern die Kanonen, aber aus den Zahlen lässt sich eine wichtige Lehre ziehen. Der KI-Boom ist weiterhin voll im Gange und davon profitiert nicht nur Nvidia.... ► Artikel lesen | |
| SOLESENCE | 1,420 | 0,00 % | Solésence, Inc.: Solésence Reports Second Quarter 2026 Financial Results | Quarterly Report Filed on Form 10-Q Company to Host Conference Call at 5:00 p.m. ET Today ROMEOVILLE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically... ► Artikel lesen | |
| KOPIN | 2,360 | +0,51 % | Fabric.AI (Nasdaq: FABC) Stockholders Ratify Kopin Strategic Partnership to Develop Neural I/o MicroLED Optical Interconnect Technology for Next Generation AI Data Centers | NEW YORK, NY, June 24, 2026 (GLOBE NEWSWIRE) -- Fabric.AI, Inc. (Nasdaq: FABC) ("Fabric.AI" or the "Company"), a fabless semiconductor company developing MicroLED-based optical interconnects for AI... ► Artikel lesen | |
| GOMSPACE | 1,140 | +0,80 % | GomSpace Group AB: GomSpace continues to support advanced lunar exploration with an 8 MEUR (89.1 MSEK) contract with a leading North American space company | GomSpace continues to support advanced lunar exploration with an 8 MEUR (89.1 MSEK) contract with a leading North American space company
The second phase accelerates development of dual-satellite... ► Artikel lesen | |
| SMOLTEK NANOTECH | 0,141 | -0,35 % | SMOLTEK NANOTECH HOLDING AB: Additional conversion of convertible loan in Smoltek completed | ||
| GAUZY | 3,950 | -1,25 % | GAUZY LTD: Gauzy Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal | TEL AVIV, Israel, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Gauzy Ltd. (Nasdaq: GAUZ) ("Gauzy" or the "Company"), a global leader in vision and light control technologies, today announced receipt of a delisting... ► Artikel lesen | |
| NANOVEU | 0,032 | +28,00 % | Nanoveu (ASX:NVU) Removes a Major Bottleneck in Its Push to Commercialise Edge AI Chips | ||
| NANOVIRICIDES | 1,140 | +8,57 % | NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox | SHELTON, CT / ACCESS Newswire / November 17, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending... ► Artikel lesen | |
| DOTZ NANO | 0,006 | +8,77 % | XFRA 57N: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CANATU | 3,555 | -2,60 % | Canatu Oyj: Shares Subscribed With Option Rights | NOTICE, NOVEMBER 09, 2026 SHARES (Record Id 370745)
A total of 11,603 shares will be traded as old shares as of November 10, 2026... ► Artikel lesen | |
| VEECO INSTRUMENTS | 30,610 | 0,00 % | Axcelis Technologies and Veeco Instruments Provide Update on Expected Timing of Merger Closing | Merger now expected to close by the end of the first quarter of 2027 BEVERLY, Mass., and PLAINVIEW, N.Y., Nov. 2, 2026 /PRNewswire/ -- Axcelis Technologies, Inc. (Nasdaq: ACLS) ("Axcelis") and Veeco... ► Artikel lesen | |
| OBDUCAT | 0,027 | 0,00 % | NGM MARKET NOTICE: #26-72 Decision by the Disciplinary Committee regarding Obducat AB (publ) |